As of June 2021, there were only two drugs approved by the FDA and EMA for the treatment of Myelofibrosis. This limited selection of treatment options has been a challenge for patients with Myelofibrosis (MF) and Myeloproliferative Neoplasms (MPNs) in general, despite the significant progress made in the treatment of other hematological malignancies in recent years. However, there is hope on the horizon as multiple new therapies are currently undergoing phase 3 trials specifically for the treatment of MF and MPNs.
Recognizing the urgent need for more effective treatment options, APLUSA leverages its extensive expertise in hematological malignancies and introduced MFsyndiTrack, a groundbreaking syndicated study. This study focuses on capturing real-world data (RWD) to monitor the treatment of patients with Myelofibrosis. By closely monitoring the impact of new treatments, MFsyndiTrack aims to provide valuable insights into the management of these patients and contribute to the development of more targeted and effective therapies.
At APLUSA, we are pioneers in syndicated patient chart audits, and we are committed to advancing the field of hematological malignancies. Through our comprehensive study, we have recently gathered data from 112 Onco-hematologists across Germany, the UK, Austria, and Canada. This extensive dataset includes the detailed analysis of 429 real-world Myelofibrosis patient charts, providing a comprehensive understanding of the current treatment landscape and patient outcomes.
With MFsyndiTrack, we aim to bridge the gap between clinical trials and real-world practice, allowing pharmaceutical companies to make informed decisions based on real-world evidence. By continually monitoring the treatment of Myelofibrosis patients, we can identify trends, challenges, and potential areas for improvement. Ultimately, our goal is to improve patient outcomes and contribute to the development of innovative therapies that can transform the lives of individuals living with Myelofibrosis and other MPNs.
Join us in our mission to enhance the understanding and treatment of Myelofibrosis. Together, we can make a difference in the lives of patients and pave the way for a brighter future in the field of hematological malignancies.
Example of a recent wave :
-
- Data available in Germany, UK, Austria, Canada
- 112 Onco-hematologists
- 429 real world Myelofibrosis patient charts